UNSPSC 51401543: Pinazepam

This classification denotes a benzodiazepine with the molecular formula C18H13ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5286RBZ882, chemically known as 7-chloro-2,3-dihydro-5-phenyl-1-propargyl-1h-1,4-benzodiazepin-2-one but generally known as pinazepam, which bears US NIH Compound Identifier 40391. European Medicines Agency schedules Pinazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09852MIG.

UNSPSC 51401543 Pinazepam is a Commodity code that captures pharmaceutical products purchased by state and local health agencies, though recent opportunities under this specific code show limited direct activity tied to the product name itself. State and local governments buying under this code primarily procure pharmaceuticals and related health products through competitive solicitation — including generic pharmaceuticals, over-the-counter products, naloxone, and drug deactivation systems — typically as part of broader health and community safety initiatives. Issuing bodies include state health departments, county public health authorities, and regional cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a significant issuing mechanism for pharmaceutical procurement across participating states, while individual county health departments such as Seminole County, Florida also solicit directly.

Recent activity spans Florida and Minnesota, with the Texas Health and Human Services Commission conducting early-stage market research. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across multiple state and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; awards were based on fixed pricing (10 percent weight), compliance and EDI capability (15 percent combined), and price competitiveness (75 percent). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling early-stage exploration of alternative pharmaceutical supply models.